The first effective example of targeted therapy is the inhibition of the BCR-ABL1 oncogene in chronic myeloid leukemia (CML) (Salesse and Verfaillie, 2002). This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.